EVEROLIMUS (AFINITOR): NEW POTENTIALS FOR THE THERAPY OF MALIGNANT TUMORS


V.A. Gorbunova

FSBI "RORC n.a. N.N. Blokhin" RAMS
The article presents the results of a clinical evaluation of the effects of the mTOR inhibitor everolimus (Afinitor) in various malignancies. The drug binds an intracellular protein, leading to inhibition of mTOR-kinase activity. Additionally, it inhibits the expression of hypoxia-inducing factor and reduces the expression of epidermal growth factor (EGFR). Originally, everolimus was approved by the U.S. FDA as a drug for 2nd line treatment of advanced renal cell carcinoma. Then, he was approved for the treatment of subependymal giant cell astrocytoma associated with tuberous sclerosis, progressive neuroendocrine tumors of the pancreas, and renal angiolipomyoma as a the complex lesions in tuberous sclerosis. HR + -, HER2- metastatic breast cancer previously treated with nonsteroidal aromatase inhibitors became the latest indication for the application of everolimus (2012). The potentials for the expanding clinical use of everolimus are discussed.

About the Autors


V.A. Gorbunova – MD, FSBI "RORC n.a. N.N. Blokhin" RAMS


Similar Articles


Бионика Медиа